Blood Loss, Hip Osteoarthritis
Conditions
Brief summary
The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).
Interventions
DRUGEnoxaparin
DRUGrivaroxaban
DRUGdabigatran
Sponsors
Centre of Postgraduate Medical Education
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* primary, end-stage hip osteoarthritis requiring total hip arthroplasty
Exclusion criteria
* inflammatory arthropathies * liver disorders * neoplastic conditions * clotting disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total blood loss by the 3rd postoperative day | 3rd day postoperatively | Measured for each individual. Measured according to the formula described by Nadler, Hidalgo and Bloch (Prediction of blood volume in normal human adults. Surgery 1962;51:224-32). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Drop in the haemoglobin value between 3rd day postop and preoperative | 3rd day postopertively | Difference between haemoglobin on the 3rd postopertive day and day before operation |
| Wound healing disturbances according to the definition of Centers for Disease Control and Prevention | 3 months postoperatively | Wound healing disturbances - diagnosis to be made according to the definition of Centers for Disease Control and Prevention (Mangram, Horan, Pearson, Silver and Jarvis. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78) |
Countries
Poland
Contacts
Primary ContactMarcin K Wasko, M.D., Ph.D.
Outcome results
None listed